Unresolved questions concerning human papillomavirus infection and transmission: A modelling perspective

Sexual Health

Volumn 7, Issue 3, 2010, Pages 368-375

  Regan, David G ^a   Philp, David J ^b   Waters, Edward K ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

dynamic model; infectiousness; knowledge gaps; mathematical transmission model; vaccination

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ACCURACY; ANUS INTERCOURSE; CIRCUMCISION; CLINICAL TRIAL; CONDOM; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EFFICACY; GENITAL TRACT INFECTION; HEALTH CARE POLICY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION RISK; INNATE IMMUNITY; MATHEMATICAL MODEL; ORAL SEXUAL CONTACT; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PREVALENCE; PROPHYLAXIS; REVIEW; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; TREATMENT RESPONSE; UTERINE CERVIX CANCER; VACCINATION; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS TRANSMISSION; WART VIRUS;

ADAPTIVE IMMUNITY; AUSTRALIA; CIRCUMCISION, MALE; CONDOMS; FEMALE; FORECASTING; HUMANS; IMMUNITY, INNATE; MALE; MASS VACCINATION; MODELS, THEORETICAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SEXUALLY TRANSMITTED DISEASES, VIRAL; UTERINE CERVICAL NEOPLASMS;

EID: 77956050462     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH10006     Document Type: Review

References (95)

1. Mu∼oz N, Manalastas R Jr, PitisuttithumP, Tresukosol D, Monsonego J, Ault K, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373: 1949-1957 doi:10.1016/S0140-6736(09)60691-7
2. Paavonen J, Naud P, Salmeron J, Wheeler C, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. Lancet 2009; 374: 301-314 doi:10.1016/S0140-6736(09)61248-4
3. The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomized placebo-controlled trial up to 6.4 years. Lancet 2009; 374: 1975-1985 doi:10.1016/S0140-6736(09)61567-1
4. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009; 199: 936-944 doi:10.1086/597309
5. Stanley M. Prospects for new human papillomavirus vaccines. Curr Opin Infect Dis 2010; 23: 70-75 doi:10.1097/QCO.0b013e328 334c0e1
6. Brisson M, Van de Velde N, Boily MC. Economic evaluation of human papillomavirus vaccination in developed countries. Public Health Genomics 2009; 12: 343-351 doi:10.1159/000214924
7. Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G. Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review. Pharmacoeconomics 2009; 27: 127-47. doi:10.2165/ 00019053-200927020-201000004
8. Dasbach EJ, Elbasha EH, Insinga RP. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006; 28: 88-100. doi:10.1093/epirev/mxj006 (Pubitemid 44289092)
9. Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes - a focused review of modelling approaches. Pharmacoeconomics 2008; 26: 191-215. doi:10.2165/00019053- 200826030-200900004
10. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005; 191: S97-106. doi:10.1086/425271 (Pubitemid 40144234)
11. Garnett GP. An introduction to mathematical models in sexually transmitted disease epidemiology. Sex Transm Infect 2002; 78: 7-12. doi:10.1136/sti.78.1.7 (Pubitemid 34206306)
12. Anderson RM, May RM. Infectious diseases of humans: dynamics and control. New York: Oxford University Press; 1991.
13. Garnett GP, Anderson RM. Sexually transmitted diseases and sexual behavior: insights from mathematical models. J Infect Dis 1996; 174: S150-61.
14. Keeling MJ, Rohani P. Modeling infectious diseases in humans and animals. Princeton: Princeton University Press; 2008.
15. Brunham RC. Insights into the epidemiology of sexually transmitted diseases from R0 = bcd. Sex Transm Dis 2005; 32: 722-724 doi:10.1097/01.olq. 0000190093.59071.4d (Pubitemid 41752556)
16. Giuliano AR, Anic G, Nyitray AG. Epidemiology and pathology of HPV disease in males. Gynecol Oncol 2010; 117: S15-9. doi:10.1016/ j.ygyno.2010.01.026
17. de Visser RO, Smith AM, Rissel CE, Richters J, Grulich AE. Sex in Australia: heterosexual experience and recent heterosexual encounters among a representative sample of adults. Aust N Z J Public Health 2003; 27: 146-154 doi:10.1111/j.1467-842X.2003.tb00802.x
18. Johnson AM, Mercer CH, Erens B, Copas AJ, McManus S, Wellings K, et al. Sexual behaviour in Britain: partnerships, practices, and HIV risk behaviours. Lancet 2001; 358: 1835-42. doi:10.1016/S0140- 6736(01)06883-6890
19. Laumann EO, Gagnon JH, Michael RT, Michaels S. The social organisation of sexuality: sexual practices in the United States. Chicago: University of Chicago Press; 2000.
20. Smith AMA, Rissel CE, Richters J, Grulich AE, de Visser RO. Australian study of health and relationships. Aust N Z J Public Health 2003; 27: 103-256. doi:10.1111/j.1467-842X.2003.tb00796.x
21. Giuliano AR, Harris R, Sedjo RL, Baldwin S, Roe D, Papenfuss MR, et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Womens Health Study. J Infect Dis 2002; 186: 462-469 doi:10.1086/341782 (Pubitemid 34876254)
22. Giuliano AR, Lu B, Nielson CM, Flores R, Papenfuss MR, Lee JH, et al. Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis 2008; 198: 827-835 doi:10.1086/591095
23. Trottier H, Mahmud S, Prado JCM, Sobrinho JS, Costa MC, Rohan TE, et al. Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination. J Infect Dis 2008; 197: 1436-1447 doi:10.1086/587698 (Pubitemid 351706468)
24. Bleeker MC, Hogewoning CJ, Berkhof J, Voorhorst FJ, Hesselink AT, van Diemen PM, et al. Concordance of specific human papillomavirus types in sex partners is more prevalent than would be expected by chance and is associated with increased viral loads. Clin Infect Dis 2005; 41: 612-620 doi:10.1086/431978 (Pubitemid 41170348)
25. Hernandez BY, Wilkens LR, Zhu X, Thompson P, McDuffie K, Shvetsov YB, et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 2008; 14: 888-894 doi:10.3201/eid1406.070616.2
26. Rowhani-Rahbar AMM, Hughes JPP, Koutsky LAP. Difficulties in estimating the male-to-female sexual transmissibility of human papillomavirus infection. Sex Transm Dis 2009; 36: 261-263 doi:10.1097/OLQ.0b013e3181901906
27. Brink AATP, Snijders PJF, Meijer CJLM. HPV detection methods. Dis Markers 2007; 23: 273-281
28. Iftner T, Villa LL. Chapter 12: human papillomavirus technologies. J Nat Cancer Inst Mono 2003; 31: 80-88
29. Keegan H, Mc Inerney J, Pilkington L, Grønn P, Silva I, Karlsen F, et al. Comparison of HPV detection technologies: hybrid capture 2, PreTect- HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens. J Virol Methods 2009; 155: 61-66 doi:10.1016/j. jviromet.2008.09.027
30. Lorincz AT. Molecular methods for the detection of human papillomavirus infection. Obstet Gynecol Clin North Am 1996; 23: 707-730
31. Villa LL, Denny L. Chapter 7: methods for detection of HPV infection and its clinical utility. Int J Gynaecol Obstet 2006; 94: S71-80.doi:10.1016/S0020- 7292(07)60013-60017
32. Zaravinos A, Mammas IN, Sourvinos G, Spandidos DA. Molecular detection methods of human papillomavirus (HPV). Int J Biol Markers 2009; 24: 215-222
33. Hopman AH, Smedts F, Dignef W, Ummelen M, Sonke G, Mravunac M, et al. Transition of high-grade cervical intraepithelial neoplasia to micro-invasive carcinoma is characterized by integration of HPV 16/ 18 and numerical chromosome abnormalities. J Pathol 2004; 202: 23-33. doi:10.1002/path.1490 (Pubitemid 38072842)
34. Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 2005; 14: 367-72. doi:10.1158/ 1055-9965.EPI-04-0410
35. Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009; 27: 6213-6221 doi:10.1200/JCO.2009.23.1670
36. Tinelli A, Leo G, Pisanò M, Storelli F, Leo S, Vergara D, et al. HPV viral activity by mRNA-HPV molecular analysis to screen the transforming infections in precancer cervical lesions. Curr Pharm Biotechnol 2009; 10: 767-771 doi:10.2174/138920109789978739
37. Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNAand RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer 2002; 94: 2199-2210 doi:10.1002/cncr.10439 (Pubitemid 34411978)
38. Winer RL, Harris TG, Xi LF, Jansen KU, Hughes JP, Feng Q, et al. Quantitative human papillomavirus 16 and 18 levels in incident infections and cervical lesion development. J Med Virol 2009; 81: 713-721 doi:10.1002/jmv.21450
39. Kösel S, Burggraf S, Engelhardt W, Olgemoller B. Increased levels of HPV16 E6*I transcripts in high-grade cervical cytology and histology (CIN II+) detected by rapid real-time RT-PCR amplification. Cytopathology 2007; 18: 290-299 doi:10.1111/j.1365-2303.2007. 00481.x
40. Peto J, Gilham C, Deacon J, Taylor C, Evans C, Binns W, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004; 91: 942-953
41. Newall AT, Brotherton JML, Quinn HE, McIntyre PB, Backhouse J, Gilbert L, et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 2008; 46: 1647-1655 doi:10.1086/587895 (Pubitemid 351706760)
42. Stanley M. Immunobiology of HPV and HPV vaccines. Gynecol Oncol 2008; 109: S15-21. doi:10.1016/j.ygyno.2008.02.003 (Pubitemid 351636109)
43. Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC, et al. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10 000 women in Costa Rica. Br J Cancer 2003; 89: 1248-1254 doi:10.1038/sj.bjc.6601272 (Pubitemid 37363412)
44. Rissel CE, Richters J, Grulich AE, de Visser RO, Smith AM. Sex in Australia: first experiences of vaginal intercourse and oral sex among a representative sample of adults. Aust N Z J Public Health 2003; 27: 131-137 doi:10.1111/j.1467-842X.2003.tb00800.x
45. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370: 59-67. doi:10.1016/S0140-6736(07)61050-2 (Pubitemid 47017468)
46. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009; 125: 1747-1754 doi:10.1002/ijc.24439
47. Schulz TF. Cancer and viral infections in immunocompromised individuals. Int J Cancer 2009; 125: 1755-1763 doi:10.1002/ijc.24741
48. Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology 2009; 384: 410-414 doi:10.1016/j.virol.2008.10.004
49. Stanley MA. Immune responses to human papilloma viruses. Indian J Med Res 2009; 130: 266-276
50. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008; 337: a769. doi:10.1136/bmj.a769
51. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-615
52. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000; 151: 1158-1171
53. Sanders GD, Taira AV. Cost effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9: 37-48.
54. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3: e138. doi:10.1371/journal. pmed.0030138
55. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13: 631-9. doi:10.1097/00001648-200211000- 00006 (Pubitemid 44698466)
56. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis 2006; 6: 21-31. doi:10.1016/S1473-3099(05) 70323-6
57. Regan DG, Philp DJ, Hocking JS, Law MG. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex Health 2007; 4: 147-163 doi:10.1071/SH07042 (Pubitemid 47339644)
58. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199: 926-935 doi:10.1086/597307
59. Haupt RM. Gardasil update: efficacy and safety in boys and men. Available online at: downloads/mtg-slides-jun09/06-2-hpv.pdf [verified June 2010].
60. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia - a randomized controlled trial. Obstet Gynecol 2006; 107: 18-27.
61. Rowhani-Rahbar A, Mao C, Hughes JP, Alvarez FB, Bryan JT, Hawes SE, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine 2009; 27: 5612-5619 doi:10.1016/j.vaccine.2009.07.027
62. Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/ 16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25: 4931-4939 doi:10.1016/j.vaccine.2007.03.049 (Pubitemid 46843434)
63. Cuzick J, Castanon A, Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Br J Cancer 2010; 102: 933-939 doi:10.1038/sj.bjc. 6605528
64. Dobson S, Dawar M, Scheifele D, Kollmann T, McNeil S, Halperin S, et al. Are 2 doses of HPV vaccine adequate in girls? 25th International Papillomavirus Conference; 2009, Malmo, Sweden.
65. International Agency for Research on Cancer. Randomized trial of 2 versus 3 doses of HPV vaccine in India. Lyon: IARC; 2010. Available online at: http://screening.iarc.fr/hpvvaccine.php [verified May 2010].
66. Burchell AN, Winer RL, de Sanjose S, Franco EL. Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24: S52-61. doi:10.1016/j.vaccine.2006.05.031 (Pubitemid 44293018)
67. D'Souza G, Agrawal Y, Halpern J, Bodison S, Gillison ML. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009; 199: 1263-1269 doi:10.1086/597755
68. Goodman M, Shvetsov Y, McDuffie K, Wilkens L, Zhu X, Ning L, et al. Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV cohort study. J Infect Dis 2008; 197: 957-966 doi:10.1086/529207 (Pubitemid 351590023)
69. Nyitray AG, Smith D, Villa L, Lazcano-Ponce E, Abrahamsen M, Papenfuss M, et al. Prevalence of and risk factors for anal human papillomavirus infection in men who have sex with women: A crossnational study. J Infect Dis 2010; In press. doi:10.1086/652187
70. Goodman MT, Shvetsov YB, McDuffie K, Wilkens LR, Zhu X, Thompson PJ, et al. Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the Hawaii HPV cohort study. J Infect Dis 2010; In press. doi:10.1086/651620
71. Piketty C, Darragh TM, Costa MD, Bruneval P, Heard I, Kazatchkine MD, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003; 138: 453-459
72. Edwards S, Carne C. Oral sex and the transmission of viral STIs. Sex Transm Infect 1998; 74: 6-10. doi:10.1136/sti.74.1.6 (Pubitemid 28201974)
73. Bajos N, Bozon M, Beltzer N, Laborde C, Andro A, Ferrand M, et al. Changes in sexual behaviours: from secular trends to public health policies. AIDS 2010; 24: 1185-1191 doi:10.1097/QAD.0b013e32833 6ad52
74. Chambers WC. Oral sex: varied behaviors and perceptions in a college population. J Sex Res 2007; 44: 28-42. doi:10.1207/s15598519 jsr4401-4
75. Remez L. Oral sex among adolescents: is it sex or is it abstinence? Fam Plann Perspect 2000; 32: 298-304. doi:10.2307/2648199
76. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95: 1772-1783
77. Maden C, Beckmann AM, Thomas DB, McKnight B, Sherman KJ, Ashley RL, et al. Human papillomaviruses, herpes simplex viruses, and the risk of oral cancer in men. Am J Epidemiol 1992; 135: 1093-1102
78. Castellsagué X, Albero G, Cleries R, Bosch FX. HPV and circumcision: a biased, inaccurate and misleading meta-analysis. J Infect 2007; 55: 91-93 doi:10.1016/j.jinf.2007.02.009 (Pubitemid 46888079)
79. Van Howe RS. Reply to "HPV and circumcision: a biased, inaccurate and misleading meta-analysis". J Infect 2007; 55: 93-96 doi:10.1016/ j.jinf.2007.02.007
80. Van Howe RS. Human papillomavirus and circumcision: a metaanalysis. J Infect 2007; 54: 490-496 doi:10.1016/j.jinf.2006.08.005 (Pubitemid 46567503)
81. Castellsague X, Bosch FX, Munoz N, Meijer CJ, Shah KV, de Sanjose S, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med 2002; 346: 1105-1112 doi:10.1056/NEJMoa011688 (Pubitemid 34984600)
82. Auvert B, Sobngwi-Tambekou J, Cutler E, Nieuwoudt M, Lissouba P, Puren A, et al. Effect of male circumcision on the prevalence of highrisk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis 2009; 199: 14-19 doi:10.1086/595566
83. Frisch M, Friis S, Kjaer SK, Melbye M. Falling incidence of penis cancer in an uncircumcised population (Denmark 1943-90). BMJ 1995; 311: 1471.
84. Gray RH, Serwadda D, Kong X, Makumbi F, Kigozi G, Gravitt PE, et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis 2010; 201: 1455-1462 doi:10.1086/652184
85. Madsen BS, van den Brule AJC, Jensen HL, Wohlfahrt J, Frisch M. Risk factors for squamous cell carcinoma of the penis - populationbased case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2008; 17: 2683-2691 doi:10.1158/1055-9965.EPI-08-0456
86. Tobian AA, Serwadda D, Quinn TC, Kigozi G, Gravitt PE, Laeyendecker O, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med 2009; 360: 1298-1309 doi:10.1056/NEJMoa0802556
87. Van Howe RS. Sampling bias explains association between human papillomavirus and circumcision. J Infect Dis 2009; 200: 832. doi:10.1086/605020
88. Viscidi RP, Shah KV. Adult male circumcision: will it reduce disease caused by human papillomavirus? J Infect Dis 2010; 201: 1447-1449 doi:10.1086/652186
89. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? Sex Transm Dis 2002; 29: 725-735 doi:10.1097/00007435-200211000-00018
90. Ho GYF, Kadish AS, Burk RD, Basu J, Palan PR, Mikhail M, et al. HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. Int J Cancer 1998; 78: 281-5. doi:10.1002/ (SICI)1097-0215(19981029) 78:33.0.CO;2-R
91. Wen LM, Estcourt CS, Simpson JM, Mindel A. Risk factors for the acquisition of genital warts: are condoms protective? Sex Transm Infect 1999; 75: 312-316 doi:10.1136/sti.75.5.312
92. Hogewoning CJ, Bleeker MC, van den Brule AJ, Voorhorst FJ, Snijders PJ, Berkhof J, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: a randomized clinical trial. Int J Cancer 2003; 107: 811-816 doi:10.1002/ijc.11474 (Pubitemid 37339736)
93. Bleeker MC, Hogewoning CJ, Voorhorst FJ, van den Brule AJ, Snijders PJ, Starink TM, et al. Condom use promotes regression of human papillomavirus- associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia. Int J Cancer 2003; 107: 804-810 doi:10.1002/ijc.11473 (Pubitemid 37339735)
94. Shew ML, Fortenberry JD, Tu W, Juliar BE, Batteiger BE, Qadadri B, et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med 2006; 160: 151-156 doi:10.1001/archpedi.160.2.151 (Pubitemid 43213859)
95. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354: 2645-2654 doi:10.1056/NEJMoa053284